文献速递垂体与肾上腺疾病

肢端肥大症新型联合方案的成本效益与疗效:一项前瞻性随机试验

Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial.
PubMed 文献 · J Clin Endocrinol Metab · 2020-01-01

该前瞻性随机开放标签平行臂研究在三级转诊垂体中心比较三种低剂量联合方案治疗肢端肥大症的成本效益与疗效,共纳入60例、52例可评估,52例中50例(96%)实现IGF-I控制,B组成本最低(月均9837±1375美元),C组最贵(月均22543±11158美元),A组居中(月均14261±1645美元)。

要点

  • 低剂量SRL联合每周培维索孟(B组)月均成本最低,为9837±1375美元。
  • 52例可评估者中50例(96%)实现IGF-I控制,各臂分别为93.3%、95.7%、100%。
  • 约30%患者需上调培维索孟剂量,不良事件发生率均低于10%。

核心结论

  • 低剂量SRL联合每周培维索孟为需要联合治疗的未控制肢端肥大症患者提供了一种实现成本效益良好且最佳生化控制的新型给药选择。

研究设计与样本

  • 前瞻性、随机、开放标签、平行臂研究,在三级转诊垂体中心进行,比较三种低剂量联合方案治疗24至32周。
  • 共纳入60例成人肢端肥大症患者,52例可评估;患者不论既往SRL应答及基线生化控制状态,按入组前12个月内任3个月期实现IGF-I正常化所需SRL剂量分层。

主要发现

  • 52例可评估者中50例(96%)实现IGF-I控制,A组14/15(93.3%)、B组22/23(95.7%)、C组14/14(100%)。
  • B组月均治疗成本最低(9837±1375美元),C组最高(22543±11158美元),A组居中(14261±1645美元)。
  • 约30%患者需上调培维索孟剂量,各臂不良事件发生率均低于10%。

关键数值与推荐

  • A组:高剂量SRL(兰瑞肽120 mg或奥曲肽长效释放剂30 mg)联合每周培维索孟40-160 mg/周。
  • B组:低剂量SRL(兰瑞肽60 mg或奥曲肽长效释放剂10 mg)联合每周培维索孟。
  • C组:低剂量SRL联合每日培维索孟15-60 mg/天。
  • 主要结局指标为完成至少24周治疗者中各臂的月治疗成本。

临床怎么用

  • 作者认为,低剂量SRL联合每周培维索孟是未控制肢端肥大症需要联合治疗时实现成本效益良好且最佳生化控制的新型给药选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Combination therapy with somatostatin receptor ligand (SRL) plus pegvisomant for patients with acromegaly is recommended after a maximizing dose on monotherapy. Lower-dose combination regimens are not well studied. OBJECTIVE: To compare cost-effectiveness and efficacy of 3 lower-dose combination regimens in controlled and uncontrolled acromegaly. DESIGN AND SETTING: Prospective, randomized, open-label, parallel arm study at a tertiary referral pituitary center. PATIENTS: Adults with acromegaly regardless of response to prior SRL and biochemical control status at baseline, stratified by an SRL dose required for insulin-like growth factor (IGF)-I normalization during any 3-month period within 12 months preceding enrollment. INTERVENTION: Combination therapy for 24 to 32 weeks on arm A, high-dose SRL (lanreotide 120 mg/octreotide long-acting release [LAR] 30 mg) plus weekly pegvisomant (40-160 mg/week); arm B, low-dose SRL (lanreotide 60 mg/octreotide LAR 10 mg) plus weekly pegvisomant; or arm C, low-dose SRL plus daily pegvisomant (15-60 mg/day). MAIN OUTCOME MEASURE: Monthly treatment cost in each arm in participants completing ≥ 24 weeks of therapy. RESULTS: Sixty patients were enrolled and 52 were evaluable. Fifty of 52 (96%) demonstrated IGF-I control regardless of prior SRL responsiveness (arm A, 14/15 [93.3%]; arm B, 22/23 [95.7%]; arm C, 14/14 [100%]). Arm B was least costly (mean, $9837 ± 1375 per month), arm C was most expensive (mean, $22543 ± 11158 per month), and arm A had an intermediate cost (mean, $14261 ± 1645 per month). Approximately 30% of patients required pegvisomant dose uptitration. Rates of adverse events were all < 10%. CONCLUSIONS: Low-dose SRL plus weekly pegvisomant represents a novel dosing option for achieving cost-effective, optimal biochemical control in patients with uncontrolled acromegaly requiring combination therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Bonert V, Mirocha J, Carmichael J, et al. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial. J Clin Endocrinol Metab. 2020. PMID: 32754748. doi:10.1210/clinem/dgaa444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。